• share
• favorite_border

The National Comprehensive Cancer Network聽(NCCN)鈥攁n alliance of leading cancer centers鈥攃elebrated 30 years of helping people with cancer to live better lives during the NCCN 2025 Annual Conference, March 28-30 in Orlando, Florida. The yearly event brings together leading minds and subject matter experts in front of a multidisciplinary audience to share the latest recommendations for cancer treatment and prevention.

• share
• favorite_border

Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news.

• share
• favorite_border

Learn more about FITWISE at RWJBarnabas Health and Rutgers Cancer Institute, an innovative clinical trial aiming to induce sustainable weight loss, improve cardiometabolic health and potentially reduce cancer recurrence during the survivorship years of patients with early-stage hormone receptor positive/Her 2 negative (HR+/Her2-) breast cancer.

• share
• favorite_border

April is Testicular Cancer Awareness Month. Thomas L. Jang, MD, MPH, FACS, is chief of urologic oncology at Rutgers Cancer Institute and RWJBarnabas Health shares what young men need to know.

• share
• favorite_border

Eric Bartee, PhD, is studying how to use viruses to fight cancer. The associate professor at the UNM Comprehensive Cancer Center has a $2 million grant to study how cells detect and rid themselves of viruses. He hopes to make oncolytic therapy, a form of immune therapy that uses viruses to alert the immune system to cancer, more effective.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range of cancer services and MD Anderson鈥檚 unparalleled patient experience closer to those living in Southwest Houston and the surrounding areas.

• share
• favorite_border

The Association of American Cancer Institutes (AACI) remains strongly opposed to the indiscriminate firing of dedicated public servants across the federal government.

• share
• favorite_border

• share
• favorite_border

Regular physical activity after treatment for stage 3 colon cancer reduces and may even eliminate disparities in survival between those with cancer and those in a general population of similar age and sex, according to new Dana-Farber Cancer Institute research.

• share
• favorite_border

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant (pre-surgical) chemotherapy and standard radiation treatment, according to new data from researchers at The University of Texas MD Anderson Cancer Center.

• share
• favorite_border

The University of Texas MD Anderson Cancer Center鈥檚 Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson鈥檚 world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.

• share
• favorite_border

In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph.D., from The University of Texas MD鈥疉nderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS).

• share
• favorite_border

The University of Texas MD Anderson Cancer Center today announced that Jeffrey E. Lee, M.D., an internationally regarded leader in the field of oncology, has been appointed chief medical executive (CME) effective April 1.

• share
• favorite_border

The FDA approval was based on results from the CABINET study, a phase 3 pivotal trial evaluating cabozantinib compared with placebo in two groups of patients with previously treated NETs: advanced pancreatic NETs and advanced extra-pancreatic NETs. The study was led by Jennifer Chan, MD, MPH, clinical director of the gastrointestinal cancer center and director of the program in carcinoid and neuroendocrine tumors at Dana-Farber Cancer Institute.

• share
• favorite_border

The Yale research, published in Science Signaling on March 25, offers new findings that could help improve therapies for glioblastoma and other aggressive cancers that are difficult to treat.

• share
• favorite_border

Nurses from Yale New Haven Health鈥檚 Smilow Cancer Hospital (SCH) will showcase their latest research from April 9鈥�13 at the 50th Annual Congress of the Oncology Nursing Society (ONS) in Denver, Colo. ONS, a professional organization comprising of more than 35,000 healthcare professionals, hosts this international event for nursing oncology professionals to exchange knowledge and advance the field of cancer care.

• share
• favorite_border

A Ludwig Cancer Research study has identified a key barrier to the efficacy of a promising combination of radiotherapy and immunotherapy for the treatment of brain metastases arising from breast cancer鈥攁nd in doing so uncovered approaches to overcoming that resistance.

• share
• favorite_border

Yale Department of Surgery oncologists and trainees at Yale Cancer Center will present new findings at the Society of Surgical Oncology (SSO) Annual Meeting in Tampa, Fla., from March 27鈥�29. The conference focuses on improving surgical cancer care for patients through educational sessions as well as oral and poster presentations for surgical oncologists, researchers, and patient advocates.

• share
• favorite_border

This week, the Association of American Cancer Institutes (AACI) delivered a letter to U.S. Department of Health & Human Services (HHS) Secretary Robert F. Kennedy, Jr., urging him to ensure stable, uninterrupted funding for the National Institutes of Health (NIH) and National Cancer Institute (NCI).

• share
• favorite_border

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric and young patients with a form of high-grade glioma. They found that the drug, already FDA-approved for certain adult cancers, was generally safe and resulted in tumor reduction visible on brain scans, as well as clinical improvement, in 3 out of 7 patients.